CVS Health stock (US1266501006): Mizuho lifts price target as shares hover in mid?$90s

CVS Health stock remains in focus after Mizuho reaffirmed its Outperform rating and raised its price target to $110, while the share price trades in the mid?$90s on the NYSE.

CVS Health stock is back in the spotlight after Mizuho reiterated its Outperform rating and raised its price target to 110 USD from 102 USD on May 20, 2026, signaling continued confidence in the company’s long?term earnings power, according to GuruFocus as of 05/20/2026. The move comes as CVS Health shares trade around 94 USD on the New York Stock Exchange, up strongly from the levels seen at the beginning of 2026, according to data from MarketBeat as of 05/19/2026.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CVS Health Corp.
• Sector/industry: Healthcare, pharmacy and managed care
• Headquarters/country: Woonsocket, United States
• Core markets: United States retail pharmacy, pharmacy benefit management, health insurance
• Key revenue drivers: Pharmacy services, retail prescriptions, health insurance premiums
• Home exchange/listing venue: NYSE (ticker: CVS)
• Trading currency: USD

CVS Health: core business model

CVS Health operates as a diversified healthcare company that combines retail pharmacies, pharmacy benefit management and health insurance operations under one corporate umbrella. The group’s integrated model is designed to capture value along the medication and care continuum, from prescription dispensing to claims processing and medical coverage.

In the United States, CVS is widely recognized for its nationwide chain of pharmacy and retail stores that offer prescription medications, over?the?counter products and basic health services such as vaccinations and limited clinical care. These locations form the consumer?facing backbone of the business, generating traffic and prescription volume that feeds into the broader healthcare ecosystem the company manages.

Beyond the stores, CVS Health runs a large pharmacy benefit management (PBM) business that negotiates drug prices, manages formularies and processes claims on behalf of employers, health plans and government programs. This segment is central to the company’s scale advantages and supports efforts to manage medical and pharmacy costs for clients while expanding CVS’s role in the prescription drug supply chain.

The company also offers health insurance and related services through a major health benefits arm, providing medical, pharmacy, dental and other coverage to individuals, employers and government program participants. By combining insurance with PBM services and retail access points, CVS Health aims to coordinate care more efficiently and keep patients within its network for both routine and complex health needs.

Main revenue and product drivers for CVS Health

Retail and pharmacy services remain a key revenue driver, as CVS Health fills large volumes of prescriptions through its store network and mail?order channels. Prescription volumes, reimbursement rates, generic drug penetration and front?store sales of health and wellness products all influence performance in this area, which tends to be highly sensitive to broader trends in U.S. healthcare utilization.

Pharmacy benefit management contributes substantially to revenue through service fees, spread income in some contracts and performance?based arrangements tied to managing total healthcare costs. The scale of covered lives, success in negotiating with drug manufacturers and client retention levels are important variables that shape the PBM segment’s financial contribution over time.

Health insurance premiums from commercial, Medicare and Medicaid plans represent another major pillar of CVS Health’s income. Enrollment trends, risk adjustment, medical cost ratios and regulatory changes can significantly affect profitability in this area. The combination of insured membership with PBM services and retail access points is designed to support more coordinated care for members.

For U.S. investors, this multi?segment structure means CVS Health’s revenue base is diversified across the healthcare value chain, but it also exposes the company to a broad set of policy, reimbursement and competitive dynamics. Shifts in drug pricing policy, Medicare and Medicaid rules, and employer benefit design can all influence how each segment performs in any given period.

Industry trends and competitive position

CVS Health operates in a U.S. healthcare market that continues to see pressure to control costs while expanding access to care. Consolidation among insurers, providers and pharmacies has created a small number of large, vertically integrated competitors, and CVS’s combination of retail footprint, PBM scale and insurance membership positions it within this group of major players.

At the same time, traditional pharmacies are facing growing competition from online and mail?order providers that target prescription refills and recurring medication needs. CVS Health has responded by expanding mail?order services, integrating digital tools into its offering and using in?store health services to differentiate its value proposition for patients who prefer physical access points.

Regulation remains a central factor for all companies in the drug distribution and insurance space. Debates around list prices, rebates, transparency and reimbursement frameworks can influence PBM economics, while Medicare and Medicaid policy changes affect both pharmacy and insurance volumes. CVS Health’s scale allows it to participate actively in these discussions, but also means it may be more directly affected by any major regulatory shifts.

Why CVS Health matters for U.S. investors

For U.S. investors, CVS Health is closely tied to the domestic healthcare system through its pharmacy, PBM and insurance operations. The company’s results can offer signals about prescription volumes, utilization patterns and cost trends across employer plans and government programs, making the stock a bellwether for certain aspects of U.S. healthcare spending.

Because CVS Health trades on the New York Stock Exchange in U.S. dollars, it is easily accessible for U.S. retail and institutional investors. The stock’s performance can be influenced by sector?wide sentiment in healthcare and by broader equity market movements, including interest?rate expectations and investor appetite for defensive versus growth?oriented names.

Investors also monitor how effectively CVS Health integrates its various business units and executes on strategies designed to increase patient engagement, such as in?store health services and digital platforms. Progress on these initiatives can affect long?term revenue growth and margin trends, which in turn shape how the market values the shares over time.

Conclusion

Mizuho’s decision to reaffirm an Outperform rating on CVS Health and raise its price target to 110 USD underscores that at least one major bank sees further upside potential, even as the shares trade in the mid?90 USD range on the NYSE. At the same time, some valuation frameworks suggest the stock may be trading above certain intrinsic value estimates, according to the GF Value indicator referenced by GuruFocus, highlighting that views on fair value can differ. Against a backdrop of evolving U.S. healthcare regulation, competitive pressure in pharmacy and PBM services, and ongoing integration of its health insurance activities, CVS Health remains a large, diversified player whose prospects are closely tied to the direction of the U.S. healthcare system. For investors, future performance will likely hinge on how effectively the company balances cost management, growth initiatives and regulatory change.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.